Articles From: Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects to Gentex Reports Second Quarter 2014 Earnings Release Date and Conference Call


Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment.
Sign-up for Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects investment picks
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus ( Streptococcus pneumoniae ) The poster (G-291), titled “Safety and Immunogenicity of a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine,” was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
Sign-up for Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014.
Sign-up for Genocea Reports Second Quarter 2014 Financial Results investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended June 30, 2014.
Sign-up for Genocea to Announce Second Quarter 2014 Financial Results on August 6, 2014 investment picks
Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study Data Submitted for Presentation at Medical Meeting Later this Year REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints investment picks
Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress investment picks
Results Suggest that Oncotype DX® Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics investment picks
17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year Positive Topline Results from Additional, Large Clinical Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints Positive Results from Second, Large Ductal Carcinoma In Situ (DCIS) Clinical Validation Study Submitted for Presentation at the San Antonio Breast Cancer Symposium in December Conference Call Today at 4:30 p.m. ET REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Second Quarter 2014 Financial Results and Business Progress investment picks
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference investment picks
2014/7/30
Recognized for positive client experience, solid company strategy and broad range of capabilities across function and industry-specific solutions NEW YORK , July 30, 2014 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in designing, transforming and running business processes and operations, has been named as a "leader" in worldwide business analytics services providers in the IDC MarketScape: "Worldwide Business Analytics BPO Services 2014 Vendor Assessment" report.
Sign-up for Genpact Business Analytics Services Named as a "Leader" in IDC MarketScape Report investment picks
2014/8/26
Resulting system of engagement will generate significant cost savings and operational efficiency for Genpact clients NEW YORK , Aug.
Sign-up for Genpact Expands Business Automation Capabilities by Partnering with Automic investment picks
2014/6/27
Current CFO Mohit Bhatia taking on role of Internal Transformation Leader NEW YORK , June 27, 2014 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in transforming and running business processes and operations, today announced that Edward J.
Sign-up for Genpact Names Edward J. Fitzpatrick as Chief Financial Officer investment picks
2014/6/19
Recognized for ability to execute and completeness of vision NEW YORK , June 19, 2014 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in transforming and running business processes and operations, has been positioned as a leader in the "Magic Quadrant for Finance and Accounting (F&A) BPO" by Gartner for the fifth consecutive year.
Sign-up for Genpact Positioned as a Leader in Gartner's Magic Quadrant for Finance and Accounting BPO for Fifth Consecutive Year investment picks
2014/7/31
Revenues of $561.6 Million, Up 5.0% Adjusted Income from Operations of $87.6 Million Cash Flow from Operations of $78.8 Million NEW YORK , July 31, 2014 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in designing, transforming and running business processes and operations, today announced financial results for the second quarter ended June 30, 2014 .
Sign-up for Genpact Reports Results for the Second Quarter of 2014 investment picks
2014/7/8
NEW YORK , July 8, 2014 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in transforming and running business processes and operations, will announce results for the second quarter ended June 30, 2014 after market close on Thursday, July 31 .
Sign-up for Genpact Schedules Earnings Announcement and Conference Call for Second Quarter 2014 Results investment picks
Expanded technology capabilities to enhance insurers' agility and customer experience NEW YORK , July 24, 2014 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in designing, transforming and running business processes and operations, has become one of the first SAP partners to optimize its business process outsourcing (BPO) solutions for the SAP® Business All-in-One for Insurance solution using SAP HANA® Cloud Platform.
Sign-up for Genpact to Leverage SAP® Solution for Insurance in the Cloud investment picks
2014/9/2
NEW YORK , Sept.
Sign-up for Genpact to Present at Citi Global Technology Conference investment picks
2014/9/5
NEW YORK , Sept.
Sign-up for Genpact to Present at Deutsche Bank Technology Conference investment picks
2014/7/22
Selected to deliver finance processes from Genpact's center in Dalian, China NEW YORK , July 22, 2014 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in transforming and running business processes and operations, today announced it has entered into a multi-year contract to deliver finance and accounting (F&A) services in the South East Asian markets for Honeywell, a Fortune 100 diversified technology and manufacturing leader.
Sign-up for Genpact to Support Honeywell in Asian Markets investment picks
SAN ANTONIO , July 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled "Methods and compositions for the detection of cancer". The patent US 8,772,226 B2 was issued July 8, 2014 .
Sign-up for GenSpera Announces US Patent for Methods and Compositions for the Detection, Imaging and Treatment of Cancer investment picks
SAN ANTONIO , June 19, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Chairman and CEO, Craig Dionne , PhD, will deliver a company overview at the 2014 BIO International Convention, on Tuesday, June 24 th , at 11:15 PDT , in San Diego, CA ( http://mybio.org/search/all?terms=GenSpera ). Dr.
Sign-up for GenSpera CEO, Craig Dionne, to Present Update on Lead Drug Candidate G-202 at 2014 Bio International Convention investment picks
Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO , July 15, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation.
Sign-up for GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting investment picks
G-202 Data in HCC Patients (Phase I and Phase II) Highly Suggestive of Positive Clinical Activity SAN ANTONIO , June 24, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation.
Sign-up for GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202 investment picks
Clinical Activity of G-202 to be presented at session for Treatment for Intermediate-Advanced Stage Disease SAN ANTONIO , July 7, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that interim data from the G-202 Phase I and Phase II trials in hepatocellular carcinoma (HCC) patients will be presented at the Fifth Annual Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting to be held July 11-13 th in Taipei , Taiwan.
Sign-up for GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei investment picks
SAN ANTONIO , June 23, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.
Sign-up for GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer" investment picks
SAN FRANCISCO , July 16, 2014 /PRNewswire/ -- Genstar Capital, a leading middle market private equity firm that focuses on investments in targeted segments of the software, financial services, healthcare, and industrial technology industries, today announced that it has completed the previously announced sale of Evolution1 ® , an industry leader in consumer directed health (CDH) payments and technology, to WEX Inc. (NYSE: WEX) for $532.5 million .
Sign-up for Genstar Capital Completes Sale of Evolution1 To WEX Inc. investment picks
http://media.marketwire.com/attachments/201109/19568_Gentex_Tag.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1140257&ProfileId=051205&sourceType=1 ZEELAND, MI --
Sign-up for Gentex Declares Quarterly Cash Dividend investment picks
http://media.marketwire.com/attachments/201109/19568_Gentex_Tag.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1128112&ProfileId=051205&sourceType=1 ZEELAND, MI --
Sign-up for Gentex Reports Second Quarter 2014 Earnings Release Date and Conference Call investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects to Gentex Reports Second Quarter 2014 Earnings Release Date and Conference Call
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices